What is Imvax?
Imvax operates at the intersection of immunology and oncology, specializing in the development of personalized, whole tumor-derived immunotherapies. The company's flagship platform technology is engineered to stimulate a patient's immune system to recognize and combat the entire antigen signature of their specific tumor. This holistic approach distinguishes Imvax from conventional targeted therapies that often focus on single antigens. The company's most advanced clinical program, IGV-001, is currently being evaluated for the treatment of glioblastoma, a highly aggressive form of brain cancer. By focusing on the complex biological landscape of solid tumors, Imvax is positioning itself as a critical player in the next generation of cancer therapeutics, aiming to improve patient outcomes through highly tailored, immune-modulating interventions.
How much funding has Imvax raised?
Imvax has raised a total of $195.7M across 5 funding rounds:
Unspecified
$14.7M
Series A
$15M
Series B
$25M
Series C
$112M
Other Financing Round
$29M
Unspecified (2017): $14.7M, investors not publicly disclosed
Series A (2019): $15M, investors not publicly disclosed
Series B (2019): $25M, investors not publicly disclosed
Series C (2020): $112M featuring Ziff Capital Partners, TLP Investment Partners, HP WILD Holding AG, Invus, and Magnetar Capital
Other Financing Round (2025): $29M, investors not publicly disclosed
Key Investors in Imvax
Invus
Invus Group is an investment firm specializing in financial advice, investment services, and consulting services. The company was founded in 1985 and is headquartered in New York City, New York.
Magnetar Capital
Magnetar Capital headquartered in Evanston, IL is a financial investment company specializing in the hedge fund and collateralized debt obligation market.
Ziff Capital Partners
An investment firm focused on providing strategic capital to high-growth companies across various sectors.
What's next for Imvax?
With the successful closure of this latest financing round, Imvax is well-positioned to advance its clinical development milestones. The strategic deployment of these funds will likely focus on expanding the reach of the IGV-001 program and potentially diversifying the company's portfolio of tumor-derived immunotherapies. As the firm transitions through its current lifecycle stage, the focus will shift toward rigorous clinical validation and the optimization of its manufacturing processes to support broader therapeutic applications. Investors and industry observers will be closely monitoring the company's progress in navigating the regulatory landscape and achieving key data readouts that could validate the efficacy of its platform in larger patient cohorts. The ongoing support from institutional backers provides the necessary runway to sustain long-term research and development efforts in the highly competitive biotechnology sector.
See full Imvax company page
